20 articles
A large multicenter study finds GLP-1 receptor agonists dramatically outperform DPP-4 inhibitors in preventing HCC recurrence and death post-resection.
GLP-1 receptor agonists may overcome Lenvatinib resistance in hepatocellular carcinoma by targeting a key glycolytic vulnerability.
New research reveals popular weight-loss medications may reduce cancer risk beyond their metabolic benefits.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
New research reveals how popular weight-loss medications could offer unexpected cancer protection benefits.
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
Large study reveals immune checkpoint inhibitors cause diabetes in 0.52% of patients, with 90% requiring hospitalization.
A phase II trial tests whether sunitinib retains activity in metastatic renal cell carcinoma after first-line immunotherapy resistance.
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Researchers discover how SIRT6 protein overcomes temozolomide resistance in deadly brain cancer by modifying histone lactylation patterns.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
Combining two targeted drugs plus dietary changes shows superior cancer-fighting potential in lab studies of breast and endometrial cancers.
A new strategy combining a TROP2-targeting drug with osimertinib may delay the inevitable resistance that undermines EGFR-mutant lung cancer treatment.
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
Zongertinib and sevabertinib earn FDA accelerated approvals for HER2-mutant NSCLC, expanding targeted therapy options for a historically hard-to-treat subset.
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
Researchers developed a new radiotracer that targets cancer cells more effectively when combined with mTOR inhibition therapy.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
A phase I/II trial combining nivolumab, ipilimumab, and lurbinectedin for relapsed SCLC was terminated early, raising questions about feasibility.
Scientists develop brain-penetrating drug that makes glioblastoma cells vulnerable to targeted elimination therapy.
